TR201200211A2 - Risedronat içeren farmasötik granüller. - Google Patents

Risedronat içeren farmasötik granüller.

Info

Publication number
TR201200211A2
TR201200211A2 TR2012/00211A TR201200211A TR201200211A2 TR 201200211 A2 TR201200211 A2 TR 201200211A2 TR 2012/00211 A TR2012/00211 A TR 2012/00211A TR 201200211 A TR201200211 A TR 201200211A TR 201200211 A2 TR201200211 A2 TR 201200211A2
Authority
TR
Turkey
Prior art keywords
granules containing
containing risedronate
pharmaceutical granules
risedronate
pharmaceutical
Prior art date
Application number
TR2012/00211A
Other languages
English (en)
Inventor
Bi̇lgi̇ç Mahmut
Original Assignee
Bi̇lgi̇ç Mahmut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bi̇lgi̇ç Mahmut filed Critical Bi̇lgi̇ç Mahmut
Priority to TR2012/00211A priority Critical patent/TR201200211A2/tr
Publication of TR201200211A2 publication Critical patent/TR201200211A2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Packages (AREA)

Abstract

Mevcut buluş kemik erimesi ve ilişkili hastalıkların önlenmesinde ve tedavisinde kullanılmak üzere risedronat içeren farmasötik formülasyonlara ilişkindir.
TR2012/00211A 2011-01-06 2012-01-06 Risedronat içeren farmasötik granüller. TR201200211A2 (tr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
TR2012/00211A TR201200211A2 (tr) 2011-01-06 2012-01-06 Risedronat içeren farmasötik granüller.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2011/00149A TR201100149A2 (tr) 2011-01-06 2011-01-06 Geliştirilmiş risedronat formülasyonu.
TR2012/00211A TR201200211A2 (tr) 2011-01-06 2012-01-06 Risedronat içeren farmasötik granüller.

Publications (1)

Publication Number Publication Date
TR201200211A2 true TR201200211A2 (tr) 2012-07-23

Family

ID=45787321

Family Applications (4)

Application Number Title Priority Date Filing Date
TR2011/00149A TR201100149A2 (tr) 2011-01-06 2011-01-06 Geliştirilmiş risedronat formülasyonu.
TR2012/00213A TR201200213A2 (tr) 2011-01-06 2012-01-06 Kombine dozaj formları.
TR2012/00211A TR201200211A2 (tr) 2011-01-06 2012-01-06 Risedronat içeren farmasötik granüller.
TR2012/00212A TR201200212A2 (tr) 2011-01-06 2012-01-06 Risedronat içeren geliştirilmiş formülasyonlar.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
TR2011/00149A TR201100149A2 (tr) 2011-01-06 2011-01-06 Geliştirilmiş risedronat formülasyonu.
TR2012/00213A TR201200213A2 (tr) 2011-01-06 2012-01-06 Kombine dozaj formları.

Family Applications After (1)

Application Number Title Priority Date Filing Date
TR2012/00212A TR201200212A2 (tr) 2011-01-06 2012-01-06 Risedronat içeren geliştirilmiş formülasyonlar.

Country Status (3)

Country Link
EP (1) EP2661258B1 (tr)
TR (4) TR201100149A2 (tr)
WO (1) WO2012093980A1 (tr)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL77243A (en) 1984-12-21 1996-11-14 Procter & Gamble Pharmaceutical compositions containing geminal diphosphonic acid compounds and certain such novel compounds
TR200900878A2 (tr) * 2009-02-05 2010-08-23 Bi̇lgi̇ç Mahmut Tek bir dozaj formunda kombine edilen farmasötik formülasyonlar

Also Published As

Publication number Publication date
WO2012093980A1 (en) 2012-07-12
TR201100149A2 (tr) 2012-07-23
EP2661258B1 (en) 2016-04-27
EP2661258A1 (en) 2013-11-13
TR201200212A2 (tr) 2012-07-23
TR201200213A2 (tr) 2012-07-23

Similar Documents

Publication Publication Date Title
PH12017501306A1 (en) Inhibitors of histone demethylases
EA201590165A1 (ru) Сдерживающие злоупотребление фармацевтические композиции для контролируемого высвобождения
IN2014MN00948A (tr)
TN2015000278A1 (en) Autotaxin inhibitors
TN2012000465A1 (en) Derivatives of 1-amino-2-cyclopropylethylboronic acid
PH12015500274B1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
BR112015010663A2 (pt) formas de dosagem de ruxolitinib de liberação sustentada
TW201129382A (en) Antibody formulation and therapeutic regimens
IN2014MN02069A (tr)
EA201991484A1 (ru) Лекарственные формы энзалутамида
IN2014DN06501A (tr)
IN2014MN00987A (tr)
IN2014MN00986A (tr)
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
HN2012000023A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
EA201300471A1 (ru) Замещенные 6-аминоникотинамиды в качестве модуляторов kcnq2/3
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
EA201201296A1 (ru) Способы лечения диабетических язв стопы
PH12014502623A1 (en) Difluoro-hexahydro-cyclopentaoxazinyls and difluoro-hexahydro-benzooxazinyls as bace1 inhibitors
TR201004464A2 (tr) Kemik erimesi için formülasyon.
PH12014502065A1 (en) Vesicular formulations
MX2013010367A (es) Composiciones y metodos para la terapia y diagnostico de influenza.
CY1116158T1 (el) Υποκατεστημενα 2-οξο- και 2-θειοξο-διυδροκινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3
IN2014DN03010A (tr)
TR201100151A2 (tr) İbandronate formülasyonu.